抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2)
ACEH; ACEII; ACE-II; Peptidyl-Dipeptidase A; ACE-related carboxypeptidase; Angiotensin-converting enzyme homolog; Metalloprotease MPROT15
- 編號(hào)UAEB886Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法間接法
- 反應(yīng)時(shí)長(zhǎng)2h, 30min
- 檢測(cè)范圍3.12-200ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于1.15ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1785 ¥ 2550 ¥ 11475 ¥ 21675 ¥ 178500
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 82-101 | 95 |
| EDTA plasma(n=5) | 86-103 | 89 |
| heparin plasma(n=5) | 79-94 | 84 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-90% | 96-103% | 97-104% | 94-101% |
| EDTA plasma(n=5) | 94-101% | 79-97% | 80-102% | 93-104% |
| heparin plasma(n=5) | 80-88% | 91-98% | 80-104% | 80-99% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板5次；
5. 加TMB底物90µL，37°C孵育10-20分鐘；
6. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將抗原包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)與連接于固相載體上的抗原結(jié)合，然后加入HRP標(biāo)記的二抗，徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UEPB886Hu61 | 血管緊張素轉(zhuǎn)化酶2(ACE2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPB886Hu01 | 血管緊張素轉(zhuǎn)化酶2(ACE2)活性蛋白 | Cell?culture;?Activity?Assays. |
| UAPB886Hu61 | 血管緊張素轉(zhuǎn)化酶2(ACE2)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPB886Hu01 | 血管緊張素轉(zhuǎn)化酶2(ACE2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPB886Hu02 | 血管緊張素轉(zhuǎn)化酶2(ACE2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB886Hu02 | 血管緊張素轉(zhuǎn)化酶2(ACE2)多克隆抗體 | WB |
| UPAB886Hu01 | 血管緊張素轉(zhuǎn)化酶2(ACE2)多克隆抗體 | WB |
| UMAB886Hu23 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB; IHC |
| UMAB886Hu24 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB; IHC |
| UMAB886Hu25 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAB886Hu21 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB; IHC |
| UMAB886Hu22 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB; IHC |
| UFAB886Hu08 | 抗血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | FCM |
| UFAB886Hu04 | 抗血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | Flow cytometry. |
| UFAB886Hu02 | 抗血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | Flow cytometry. |
| UFAB886Hu06 | 抗血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | Flow cytometry. |
| USEB886Hu | 血管緊張素轉(zhuǎn)化酶2(ACE2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UAEB886Hu | 抗血管緊張素轉(zhuǎn)化酶2抗體(Anti-ACE2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| ULMB886Hu | 血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Nature Medicine | Angiotensin-Converting Enzyme 2 Overexpression Remarkably Ameliorated Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition [MolMed: 10_11_liu] |
| Journal of Cancer Therapy | Plasma Levels of Angiotensin-Converting Enzymes 1 and 2 and AGTR2 (T1247G and A5235G) Gene Polymorphisms Are Associated to Breast Cancer Progression. [Scirp: Source] |
| Reprod Toxicol.? | ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats [Pubmed:25205467] |
| Intensive Care Medicine Experimental | Angiotensin converting enzymes in patients with acute respiratory distress syndrome [Content: 3] |
| Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis [S0021967317311858] |
| Journal of Clinical Pharmacy and Therapeutics | Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites. [pubmed:28895159] |
| Innate?Immunity? | Lipoxin A attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis [Pubmed:29969931] |
| Journal of?Surgical?Research | Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomy [Pubmed:29506841] |
| canadian journal of physiology and pharmacology | Could cardioprotective effect of ACE2 activator “diminazene aceturate” is more potent than ACE inhibitor “Enalapril” on acute myocardial infarction in rats? [Pubmed: 30840489] |
| Intensive Care Medicine | Angiotensin-converting enzymes in acute respiratory distress syndrome [] |
| BioMed Research International | AVE 0991 Attenuates Pyroptosis and Liver Damage after Heatstroke by Inhibiting the ROS-NLRP3 Inflammatory Signalling Pathway [] |
| Heart?and?vessels | Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS axis and coronary heart disease [Pubmed: 31359146] |
| Medicine | Alteration and association between serum ACE2/angiotensin (1-7)/Mas axis and oxidative stress in chronic kidney disease: A pilot study [Pubmed: 32756181] |
| American Journal of Respiratory and Critical Care Medicine | Equilibrium Angiotensin Metabolite Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin Converting Enzyme Inhibition [Pubmed: 32628511] |
| Clinical Research in Cardiology | Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease [33280062] |
| Clinical & Translational Immunology | Pattern of circulating SARS?\CoV?\2?\specific antibody?\secreting and memory B?\cell generation in patients with acute COVID?\19 [33552508] |
| researchsquare | Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis [33855640] |
| Viruses | Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera [] |
| Sci Rep | Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury [34907257] |
| European Journal of Clinical Investigation | Angiotensin‐converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end‐stage kidney disease [Pubmed:35366343] |
| Metabolites | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats [Pubmed:35448480] |
